Chardan Capital Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a report issued on Thursday,Benzinga reports. They presently have a $12.00 price target on the stock. Chardan Capital’s price objective suggests a potential upside of 172.73% from the stock’s current price.

Several other analysts also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, March 3rd. Finally, UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.09.

Taysha Gene Therapies Stock Down 3.5%

Shares of Taysha Gene Therapies stock opened at $4.40 on Thursday. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -12.94 and a beta of 1.02. The stock has a 50-day simple moving average of $4.63 and a 200-day simple moving average of $4.55. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $6.02. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to the consensus estimate of $1.89 million. Taysha Gene Therapies had a negative return on equity of 62.55% and a negative net margin of 1,144.97%. On average, equities research analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00. Following the transaction, the insider owned 1,006,439 shares of the company’s stock, valued at approximately $4,740,327.69. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kamran Alam sold 78,968 shares of the company’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00. Following the transaction, the chief financial officer owned 1,467,635 shares of the company’s stock, valued at approximately $6,971,266.25. The trade was a 5.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 598,623 shares of company stock valued at $2,822,188. 3.78% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Vestal Point Capital LP raised its position in shares of Taysha Gene Therapies by 150.0% during the fourth quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after buying an additional 8,250,000 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Taysha Gene Therapies by 2.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock worth $75,310,000 after buying an additional 309,031 shares in the last quarter. Vanguard Group Inc. increased its stake in Taysha Gene Therapies by 3.3% during the fourth quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock valued at $72,973,000 after acquiring an additional 418,192 shares during the period. Octagon Capital Advisors LP increased its stake in Taysha Gene Therapies by 17.7% during the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after acquiring an additional 1,892,500 shares during the period. Finally, State Street Corp raised its holdings in Taysha Gene Therapies by 49.1% in the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after acquiring an additional 3,553,619 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Key Taysha Gene Therapies News

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Q4 2025 results topped expectations — reported EPS of ~$-0.087 vs. consensus ~$-0.096 and revenue of $5.49M well above estimates; management highlighted momentum on programs and financial results. Earnings Call Transcript (InsiderMonkey)
• Positive Sentiment: TSHA‑102 pivotal trial enrollment advancing and company says it’s on track to complete dosing in Q2 2026 with a 2026 BLA submission path — a clear clinical catalyst for future value. BLA Submission Path (MSN)
• Positive Sentiment: Analyst optimism picked up — Needham raised its price target to $12 (buy) and Chardan reaffirmed a $12 buy target, signaling sizable upside from current levels and likely contributing to increased attention. Analyst Coverage (Benzinga)
• Positive Sentiment: Company highlighted a strong cash position on the earnings call, which supports ongoing pivotal enrollment and development activity. Earnings Highlights (Yahoo Finance)
• Neutral Sentiment: Full earnings/management commentary and call transcripts are available from multiple outlets for investors who want the full details and Q&A. Transcript (Seeking Alpha)
• Negative Sentiment: Company remains unprofitable with a very negative net margin and negative return on equity; development risk and cash burn remain material risks until regulatory milestones or commercialization are achieved. Full Results & Corporate Update (GlobeNewswire)

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.